News Information

News

Corporate News

Industry News

Notice Announcement

Home page

Breaking! Large clinical study confirms the "killing power" of hyperthermic intraperitoneal chemotherapy on tumors.

In recent years, the incidence of malignant tumors in the abdominal cavity in our country, such as gastric cancer, colorectal cancer, and ovarian cancer, has shown a significant upward trend. Most cases are diagnosed at an advanced stage, and postoperative peritoneal implantation metastasis is a global challenge.

2018-11-22 21:26

　　In recent years, the incidence of malignant tumors in the abdominal cavity in our country, such as gastric cancer, colorectal cancer, and ovarian cancer, has shown a significant upward trend, and most are diagnosed at an advanced stage, making postoperative peritoneal implantation metastasis a global challenge.

　　On October 27, the Second South China International Oncology Summit Forum and the Fifth National Tumor Cavity Hyperthermic Perfusion Treatment Seminar were held in Guangzhou. More than thirty authoritative experts from home and abroad gave academic reports and shared special cases focusing on the cutting-edge hotspots and clinical difficulties of cavity hyperthermic perfusion treatment and malignant tumor treatment.

　　According to reports from Southern Daily, large-scale multicenter clinical studies have confirmed that abdominal hyperthermic perfusion chemotherapy has a definite effect on improving the prognosis and survival of patients with advanced abdominal tumors. The conference established expert consensus on the standardized use of cavity hyperthermic perfusion treatment, further improving standards and promoting this new technology to benefit more cancer patients.

　　The global challenge of abdominal tumors

　　Malignant tumors in the abdominal cavity often experience peritoneal implantation metastasis at the time of diagnosis or after surgery. The so-called implantation metastasis occurs when tumor cells break through the outer membrane of organs and fall off or metastasize into the abdominal cavity. This is a natural phenomenon in tumor development and may also be caused by intraoperative bleeding. "They are like 'little tails' of malignant tumors that escape everywhere, elusive and countless, making it difficult for doctors to detect during surgery, and postoperative chemotherapy is also hard to completely eliminate. However, it is the most common, frequent, and severe complication of malignant tumors in the abdominal cavity, and it is also a sign of malignant tumors reaching an advanced stage," said Cui Shuzhong, director of the Affiliated Tumor Hospital of Guangzhou Medical University.

　　Taking gastric cancer as an example, the current situation of diagnosis and treatment of peritoneal metastasis in gastric cancer in our country is very severe. Peritoneal metastasis is the primary cause of death in patients with advanced gastric cancer. Research reports indicate that nearly 400,000 gastric cancer patients die from tumor recurrence each year, with about 70% related to peritoneal metastasis. The incidence and mortality rates of gastric cancer rank second among malignant tumors in our country, with 20% already having peritoneal implantation metastasis or concurrent malignant ascites at the first diagnosis. After radical surgical resection, 50% will experience peritoneal implantation metastasis or concurrent malignant ascites.

　　In the past, clinical doctors were at a loss when faced with cases of peritoneal implantation metastasis, but with the development of tumor hyperthermic perfusion treatment technology, this situation is gradually changing.

　　The principle of hyperthermic perfusion treatment is: normal tissues can withstand temperatures above 47°C for more than one hour, while malignant tumor cells can only withstand temperatures of 43°C. If hyperthermia is combined with chemotherapy, the anti-tumor effect of the chemotherapy drugs will be significantly enhanced under heated conditions.

　　Multicenter clinical studies validate the effectiveness.

　　The biggest challenge of hyperthermic chemotherapy is precise temperature control. The higher the constant temperature in the abdominal cavity, the better the treatment effect, but if the treatment temperature is too high, it can cause irreversible thermal damage to the human body and even endanger life.

　　In the face of this tricky problem, Professor Cui Shuzhong, director of the Affiliated Tumor Hospital of Guangzhou Medical University, led a team to overcome the bottleneck, achieving precise temperature control, accurate positioning, and precise elimination in hyperthermic chemotherapy technology, referred to as Precise Abdominal Hyperthermic Perfusion Technology (P-HIPEC).

　　Director Cui Shuzhong introduced that the P-HIPEC patented technology passed the product technical review by the National Medical Products Administration in December 2009, obtaining a product registration certificate, making hyperthermic perfusion chemotherapy an effective treatment method for peritoneal metastasis of tumors. Currently, the precise HIPEC technology is being promoted and applied in over 300 large tertiary hospitals across 24 provinces and cities nationwide, successfully treating nearly 100,000 cancer patients.

　　Currently, six large multicenter clinical studies have been conducted nationwide around the P-HIPEC technology, among which the HIPEC-01 project was designed by the Affiliated Tumor Hospital of Guangzhou Medical University and Harvard Medical School, in collaboration with 20 large tertiary hospitals at home and abroad. This year, the First Affiliated Hospital of Sun Yat-sen University, Qingdao University Affiliated Hospital, Sichuan Provincial People's Hospital, and Wuhan University Zhongnan Hospital have newly joined the project. Nearly 500 cases have been enrolled in this project, and it will include a larger range of patients in the future to further explore its value in the treatment of advanced gastric cancer, providing real and reliable research results to offer clinical basis for formulating the best comprehensive treatment plan.

　　Professor Cui Shuzhong introduced that the study shows that P-HIPEC has a definite effect in the treatment of malignant tumors, significantly improving prognosis, extending the overall survival of patients, and increasing the 3-year overall survival rate of patients with stage IV gastric cancer, stage IV colorectal cancer, and advanced ovarian cancer by 10.4% to 13%. For superficial bladder cancer after transurethral resection, adding bladder hyperthermic perfusion chemotherapy can reduce the 3-year recurrence-free survival rate by 13.1%, effectively preventing recurrence; the effective rate for treating malignant ascites is over 90%.

　　Professor Wang Jiping from Harvard Medical School, who is involved in the high-level university construction and flexible talent introduction at the Affiliated Tumor Hospital of Guangzhou Medical University, told reporters that hyperthermic chemotherapy technology can kill free tumor cells in the abdominal cavity on one hand, and on the other hand, it can act as a "scorched earth policy" on the peritoneal surface, turning it into a "barren land" where tumor cells cannot grow.

　　Professor Liang Han, director of the gastric tumor department at Tianjin Medical University Cancer Hospital, and Professor Wang Huiming from the Affiliated Hospital of Taiwan University of Traditional Chinese Medicine both stated in interviews that hyperthermic chemotherapy technology should be applied before or early in the occurrence of peritoneal metastasis to achieve a preventive effect and reduce the recurrence rate of malignant tumors in the abdominal cavity.

　　It is reported that the "Precise Cavity Hyperthermic Perfusion Treatment Technology" proposed for the first time by the Affiliated Tumor Hospital of Guangzhou Medical University is an important construction content of the oncology discipline group at Guangzhou Medical University. This year also marks the 60th anniversary of the establishment of Guangzhou Medical University. President Wang Xinhua of Guangzhou Medical University introduced that the university is fully promoting the construction of high-level universities, actively building 13 high-level discipline groups, among which the oncology discipline group relying on the Affiliated Tumor Hospital is one of them.

[Source] Southern Media Group Southern+ Client

keywords:

Abdomen,Tumor